Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 9701–9750 of 18658
As previously disclosed, Mr. Cheng is relocating to St. Louis in connection with the Company’s plan to appoint him as Chief Executive Officer upon the retirement of Anna Manning, the Company’s current Chief Executive Officer, on December 31, 2023.
As previously disclosed, Mr. Cheng is relocating to St. Louis in connection with the Company’s plan to appoint him as Chief Executive Officer upon the retirement of Anna Manning, the Company’s current Chief Executive Officer, on December 31, 2023.
On April 17, 2023, Nektar Therapeutics (the “Company”) announced that Jillian Thomsen will step down as the Chief Financial Officer of the Company effective as of April 17, 2023
Treasure Global Inc (the “Company”) and Michael Chan Meng Chun entered into an Executive Employment Agreement on June 21, 2023 (the “Employment Agreement”), pursuant to which Mr. Chan was appointed as the Company’s Chief Financial Officer effective as of July 31, 2023.
The Company’s board of directors appointed Dr. Uttam Yashwant Patil to replace Dr. Doong as the Company’s CEO.
Dr. Howard Doong, the Chief Executive Officer (“CEO”) of ABVC BioPharma, Inc. (the “Company”), notified the Company of his resignation, effective June 21, 2023.
On June 16, 2023 Carl Pombar resigned as Chief Financial Officer (including as principal financial and accounting officer) of African Gold Acquisition Corporation) effective immediately.
On June 21, 2023, the Company and its former Chief Executive Officer Michael D. Farkas entered into a separation and general release agreement, dated as of June 20, 2023 (the “Separation Agreement”) pursuant to Mr. Farkas’ May 1, 2023 termination of employment
On June 1, 2023, the Company’s Board of Directors appointed Dean Medwid as Chief Executive Officer.
Dominic Colvin stepped down as the Chief Executive Officer (“CEO”) of CannPharmaRX, Inc. (the “Company”) effective June 1, 2023.
On June 15, 2023, the Board of Directors (the “Board”) of Turtle Beach Corporation (the “Company”) appointed Cris Keirn, the Company’s Senior Vice-President, Global Sales, to serve as the Company’s Interim Chief Executive Officer and as its principal executive officer, both effective July 1, 2023.
On June 22, 2023, Christie Kelly notified Realty Income Corporation (the “Company”) that she will retire from her service to the Company as Executive Vice President, Chief Financial Officer and Treasurer of the Company, effective December 31, 2023
On June 22, 2023, the Company announced its appointment of Jonathan Pong as Executive Vice President, Chief Financial Officer and Treasurer of the Company, effective as of January 1, 2024
the departure of Jeffrey L. Tate from such position
On June 21, 2023, the Company’s Board of Directors appointed Benjamin M. Burns, age 45, as Executive Vice President and Chief Financial Officer, effective immediately
the Board appointed Carlos R. Quezada, age 52, to serve as the Company’s Chief Executive Officer (“CEO”), effective June 21, 2023
On June 20, 2023, Jason Field, RGC Resources, Inc.’s (the “Company”) Vice President, Chief Financial Officer and Treasurer, notified the Company of his voluntary resignation, effective August 4, 2023.
On June 20, 2023, Stephen E. Guthrie, Senior Vice President and Chief Financial Officer of each of Hawthorn Bancshares, Inc. (the "Company") and Hawthorn Bank (the "Bank"), notified the Company of his decision to retire from the Company and Bank, effective September 1, 2023.
On June 21, 2023, Integra LifeSciences Holdings Corporation (the “Company”) announced the appointment of Lea Daniels Knight to serve as its Executive Vice President and Chief Financial Officer effective June 28, 2023.
On June 16, 2023, Samuel D. Riccitelli resigned from his position as Interim President and Chief Executive Officer of Biocept, Inc. (the “Company”), and from the Company’s Board of Directors (the “Board”), effective June 16, 2023.
On June 16, 2023, the Board appointed Antonino Morales as the Company’s President and Chief Executive Officer.
On June 18, 2023, Christopher Chipman notified the Chairman of the Board of Directors of the Company of his decision to resign from his position as the Company’s Chief Financial Officer to pursue other opportunities.
Effective as of June 20, 2023, the Board of Directors of Virpax Pharmaceuticals, Inc. (the “Company”) appointed Vinay Shah to serve as the Company’s Chief Financial Officer.
On June 14, 2023, following the previously reported departure of the former Chief Financial Officer of Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”), the Company’s board of directors appointed William Elder, Diffusion’s General Counsel and Corporate Secretary, as the Company’s principal financial officer.
replacing Brent Suen as President and filling the role of Chief Operating Officer which was previously vacant. Brent Suen will continue in his role as Chief Executive Officer.
Chris Suh to step down as Chief Financial Officer with a departure date of June 30, 2023
Stuart Canfield was appointed Executive Vice President, Chief Financial Officer, effective June 20, 2023
The agreement provides for Ms. Rentler to continue as CEO through and until January 31, 2026 (the end of fiscal year 2025), subject to any earlier selection of a successor as CEO, at which time Ms. Rentler will cease to be the Company’s Chief Executive Officer, and will become a Senior Advisor for the remainder of her employment term, through March 31, 2027.
Christopher Young, who has served as the Company’s Interim Chief Executive Officer since January 2, 2023, will step down from that role effective the same date, and will continue in his role as Chief Financial Officer and Treasurer.
appointed Michael Christenson as the Company’s Chief Executive Officer, effective as of July 1, 2023.
On June 13, 2023, Salona Global Medical Device Corporation (the "Company") exercised its right to terminate the employment of Luke Faulstick as the Company's President and Chief Executive Officer.
On June 13, 2023, upon terminating Mr. Faulstick, the Company appointed Michael Seckler, 58, to the position of Interim Chief Executive Officer, effective immediately.
On June 20, 2023, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing the appointment of Jennifer Cote as the Company’s Chief Financial Officer and Treasurer effective as of June 19, 2023.
John C. Redett, 55, Head of Global Financial Services, will become Chief Financial Officer and Head of Corporate Strategy, effective October 1, 2023.
On June 20, 2023, The Carlyle Group Inc. (the “Company” or “Carlyle”) announced that Curtis L. Buser, Chief Financial Officer, will retire from the Company, effective December 31, 2023.
Mr. Darrell will replace Benno Dorer, who has been serving as the Company’s Interim President and Chief Executive Officer
approved the appointment of Bracken Darrell as President and Chief Executive Officer of the Company, effective as of July 17, 2023
Effective immediately, on June 16, 2023, the Board of Directors (the “ Board ”) of Cano Health, Inc. (the “ Company ”) elected the Company’s current Chief Strategy Officer, Mr. deMarquette (“ Mark ”) Kent, as the Company’s Interim Chief Executive Officer (the “ Interim CEO ”).
Mr. Kent will replace Dr. Marlow Hernandez, who tendered his resignation as the Company’s Chief Executive Officer, as well as all positions he holds at the Company’s subsidiaries, effective immediately on June 16, 2023.
Brian Linscott departing the Company as of June 16, 2023
appointing Kirk Davis as Chief Executive Officer and nominating Mr. Davis to the Board, effective as of June 19, 2023
the Company appointed Timothy Mullany as its Chief Financial Officer, effective as of July 10, 2023
the Company has appointed Ryan Blust, the Company’s Vice President, Finance, to serve as its Interim Chief Financial Officer, effective immediately
Mr. D’Amico’s resignation as Chief Financial Officer was effective immediately.
As of July 5, 2023, Ricky Hopson will cease to serve as Interim Chief Financial Officer and principal financial officer of the Company and, after supporting Mr. Masanovich in his transition, will return to a business leadership role at the Company.
Catalent, Inc. (“ Catalent ” and, together with its subsidiaries, the “ Company ”), announced the appointment of Matti Masanovich as Senior Vice President and Chief Financial Officer, effective as of July 5, 2023.
On June 20, 2023, Visa Inc. (“Visa,” or the “Company”) announced that Chris Suh, 52, has been appointed to serve as Executive Vice President, Chief Financial Officer (“CFO”) of the Company, effective August 1, 2023.
Mr. Suh succeeds Vasant Prabhu, who is departing the Company on September 30, 2023.
On June 20, 2023, Hovnanian Enterprises, Inc. (the “Company”) announced that J. Larry Sorsby, Executive Vice President and Chief Financial Officer, intends to retire from the Company effective October 31, 2023.
In connection with Mr. Sorsby’s retirement, Brad G. O’Connor, age 52, has been appointed Chief Financial Officer, effective November 1, 2023.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.